Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

UBS
QuintilesIMS
Cantor Fitzgerald
Harvard Business School
Covington
McKesson

Generated: July 18, 2019

DrugPatentWatch Database Preview

Patent: 9,913,852

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,913,852
Title:Method of treating and preventing secondary hyperparathyroidism
Abstract: The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient\'s normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient\'s normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D.sub.3, and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin D.sub.3 for 25-hydroxyvitamin D repletion and/or maintenance.
Inventor(s): Bishop; Charles W. (Miami Beach, FL), Crawford; Keith H. (Lone Tree, CO), Messner; Eric J. (Lake Forest, IL), Petkovich; P. Martin (Kingston, CA), Helvig; Christian F. (Markham, CA)
Assignee: OPKO IRELAND GLOBAL HODLINGS, LTD. (Grand Cayman, KY) OPKO RENAL, LLC (Miami, FL)
Application Number:15/220,963
Patent Claims:see list of patent claims

Details for Patent 9,913,852

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23 ➤ Try a Free Trial OPKO IRELAND GLOBAL HODLINGS, LTD. (Grand Cayman, KY) OPKO RENAL, LLC (Miami, FL) ➤ Try a Free Trial RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23 ➤ Try a Free Trial OPKO IRELAND GLOBAL HODLINGS, LTD. (Grand Cayman, KY) OPKO RENAL, LLC (Miami, FL) ➤ Try a Free Trial RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23 ➤ Try a Free Trial OPKO IRELAND GLOBAL HODLINGS, LTD. (Grand Cayman, KY) OPKO RENAL, LLC (Miami, FL) ➤ Try a Free Trial RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23 ➤ Try a Free Trial OPKO IRELAND GLOBAL HODLINGS, LTD. (Grand Cayman, KY) OPKO RENAL, LLC (Miami, FL) ➤ Try a Free Trial RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 9,913,852

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2008008608 Jan 17, 2008
World Intellectual Property Organization (WIPO) 2008008608 Mar 20, 2008
United States of America 2009209501 Aug 20, 2009
United States of America 2013178451 Jul 11, 2013
United States of America 2016331765 Nov 17, 2016
United States of America 2018296576 Oct 18, 2018
United States of America 8329677 Dec 11, 2012
Country Patent Number Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Merck
QuintilesIMS
Cipla
Fuji
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.